You're contacting media contact of this press release

Title: Improzo Inc. Transforms Customer Engagement in Life Sciences with AI-Powered Platform

United States, 15th Jan 2026 - Improzo Inc. is redefining customer engagement in the life sciences industry by combining advanced technology with deep domain expertise. Co-founded by Inderpreet Kambo and Abhishek Trigunait, Improzo is a tech startup focusing on helping pharmaceutical and biotech organizations improve how they engage healthcare professionals, manage accounts, and operationalize decisions across commercial and medical teams. The platform integrates directly with enterprise systems such as Veeva CRM, Salesforce, Snowflake, and Tableau, enabling faster and compliant execution without re-platforming.Addressing the Industry ChallengeImprozo was founded to address a persistent industry challenge: while life sciences organizations have invested heavily in CRM systems, data lakes, and analytics tools, frontline teams still struggle with last-mile execution. Insights are generated, but they often remain disconnected from real-world action. Improzo closes this gap by embedding agentic AI directly into CRM workflows to guide compliant action at the point of engagement.The Platform's Core: Modular Agent ArchitectureAt the core of Improzo’s platform is a modular agent architecture that operates natively within the CRM. These agents continuously reason over CRM activity, enterprise data stored in Snowflake, unstructured medical and commercial content, and business rules to support use cases such as next-best action, MSL engagement prioritization, dynamic targeting, and account-level orchestration. Improzo leverages modern enterprise AI technologies, including Snowflake Cortex for secure, governed AI inference to deliver real-time intelligence while maintaining strict data governance, auditability, and compliance.Execution-First, Collaborative ApproachImprozo different...

This press release is issued by King Newswire